BOLERO-2 , a phase III randomized trial , compared EVE ( 10mg/d ) and placebo ( PBO ) , both plus EXE ( 25 mg/d ) , in 724 postmenopausal women with HR ( + ) advanced breast cancer recurring/progressing after treatment with NSAIs .